Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
THE PURPOSE OF THE STUDY is to optimize the therapy of patients with primary B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) by including monoclonal bispecific antibodies in
post-induction treatment with simultaneous reduction of chemotherapy.
QUESTIONS AND OBJECTIVES OF THE STUDY:
- to determine the efficacy and feasibility of chemotherapy and immunotherapy combination
in comparison with standard PCT in children and adolescents with newly diagnosed
BCP-ALL;
- to determine the safety and toxicity of chemotherapy and immunotherapy combination in
comparison with standard PCT in children and adolescents with newly diagnosed BCP-ALL;
- to determine the possibility of chemotherapy reducing when immunotherapy is included in
the treatment regimen without loss of effectiveness;
- to determine the possibility of reducing the maintenance therapy duration to 1 year when
immunotherapy is included in the treatment regimen without loss of effectiveness.
Phase:
N/A
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology